Skip to main content
Clinical Trials/NCT06542926
NCT06542926
Not yet recruiting
Not Applicable

Electronic Dataset of NON-COlorectal Liver METastases Undergoing Liver Resection

Azienda Ospedaliero Universitaria Maggiore della Carita0 sites300 target enrollmentJanuary 1, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Liver Metastases
Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Enrollment
300
Primary Endpoint
Overall Survival
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Liver metastases (LM) are common in various types of malignant diseases, either at the diagnosis of the primary tumour or at a later time point. While the resection of colorectal LM (CRLM) is a well-established procedure, with survival rates superior to chemotherapy alone, controversial data still exist on liver resection for non-colorectal LM (NCRLM) (2, 3). These patients comprise a diverse and heterogeneous group usually excluded from surgery due to advanced tumour stage or the presence of concomitant extrahepatic disease. To date, no randomized clinical trial on the surgical treatment of NCRLM has been conducted, and only few retrospective reports are available.The scope of this research project is to develop a large registry of patients undergoing liver surgery for non-colorectal liver metastases.

Registry
clinicaltrials.gov
Start Date
January 1, 2025
End Date
June 30, 2029
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Responsible Party
Principal Investigator
Principal Investigator

Matteo Donadon

Professor of Surgery

Azienda Ospedaliero Universitaria Maggiore della Carita

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Overall Survival

Time Frame: From date of enrollment until the date of death from any cause assessed up to 36 months

Overall Survival defined as the time elapsed between the date of resective surgery and the date of death for any reason. Patients who are surviving at the end of observation will be considered "censored" at the date of the last available follow-up.

Secondary Outcomes

  • Disease-free Survival(From date of enrollement until the date of first documented progression assessed up to 36 months)

Similar Trials